Investor Resources

Investor Presentation

Quarterly Corporate Update

Corporate Update Q&A

Regulation of Human Research with LSD in The United States

Year-end 2020 Management's Discussion and Analysis

2020 Audited Annual Consolidated Financial Statements

Third Quarter 2020 Management's Discussion and Analysis

Third Quarter 2020 Consolidated Financial Statements

Second Quarter 2020 Consolidated Financial Statements

Second Quarter 2020 Management's Discussion and Analysis

Q2 2020 Earnings Call Recording

2019 Audited Annual Consolidated Financial Statements

Year-end 2019 Management's Discussion and Analysis

2019 Year End Earnings Call & Corporate Update

First Quarter 2021 Management's Discussion and Analysis

First Quarter 2021 Consolidated Financial Statements

Second Quarter 2021 Consolidated Financial Statements

Second Quarter 2021 Management's Discussion and Analysis

MindMed Sedar Profile

Audit Committee Charter

Compensation Nomination and Governance Charter

Insider Trading Policy

Majority Voting Policy

Policy RE Diversity of Executive Officers

Policy RE Diversity on Board

Privacy Policy

Policy RE Anti-Money Laundering and Anti-Terrorist Financing

Board of Directors Charter

Anti-Bribery and Anti-Corruption Policy

Nasdaq Statement of Governance Differences